Ardelyx licenses NaPi2b inhibitors to Sanofi

Ardelyx Inc. (Fremont, Calif.) granted Sanofi (Euronext:SAN; NYSE:SNY) exclusive, worldwide rights to develop and commercialize Ardelyx's RDX002 program of solute carrier family 34 sodium phosphate member 2 ( SLC34A2; NaPi2b) inhibitors. Ardelyx will receive an undisclosed upfront payment and is eligible for up to $198 million in milestones, plus royalties. The compounds in the program are in discovery and preclinical development to treat hyperphosphatemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD). Ardelyx retains an option to co-promote the compounds in the U.S. ...